Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Karuna Therapeutics to $258 from $274 and keeps a Buy rating on the shares post the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KRTX:
- Karuna Therapeutics names Jason Brown as CFO, Jonathan Rosin as CHRO
- Karuna Therapeutics reports Q2 EPS ($2.75), consensus ($2.78)
- 3 Best Stocks to Buy Now, 7/20/2023, According to Top Analysts
- Karuna Therapeutics initiated with an Overweight at Morgan Stanley
- Karuna pullback brings buying opportunity, says William Blair